Neuropilin-1 (NRP-1), a vascular endothelial growth factors and semaphorin receptor functioning as mediator of angiogenesis and neuronal guidance, is expressed by various solid tumors. The importance of NRP-1 in hematological malignancies such as acute myeloid leukemia (AML) remains to be elucidated. Therefore, we determined NRP-1 expression by immunohistochemical analysis of bone marrow biopsies of patients with newly diagnosed, untreated AML. The expression of NRP-1 was significantly increased in AML patients (n ¼ 76; median 12.9 arbitrary units (a.u.)) as compared with controls (n ¼ 38; median 2.75 a.u.). Survival was significantly poorer in patients with high (4median) versus low (pmedian) NRP-1 expression levels with 5-year overall survival rates of 16.9 versus 49.6% (P ¼ 0.050). In conclusion, our data provide evidence of increased NRP-1 expression in AML with significant correlation to survival. Thus, NRP-1 might constitute a promising target for antileukemic and antiangiogenic treatment strategies in AML.
Introduction
In analogy to solid tumors, emerging data suggest the requirement of angiogenesis also for the development and progression of hematopoietic malignancies. Recently, we and others reported increased angiogenesis in the bone marrow of patients with acute myeloid leukemia (AML). [1] [2] [3] [4] [5] Neuropilins (NRP) are membranous receptors capable of binding two disparate ligands, class 3 semaphorins (Sema) and vascular endothelial growth factors (VEGF), and regulating two diverse systems, neuronal guidance and angiogenesis. NRPs are expressed in many types of cancer cells, in endothelial cells and in additional many types of normal diploid cell types. 6 In bone marrow, NRP-1 expression was detected on bone marrow stromal cells suggesting mediating interactions between stroma and primitive hematopoietic cells 7 and on bone marrow adipocytes indicating a regulatory role in adipocyte activity. 8 Furthermore, it was reported that NRP-1 expression on fetal liver hematopoietic cells may serve as a source of vascular development 9 and is involved in the VEGF-dependent differentiation of human bone marrow progenitor cells into endothelial precursor cells. 10 In a systemic leukemia mouse model, it was demonstrated that AML progression was induced by VEGF and that a soluble form of NRP-1 significantly inhibited AML progression in vivo. 11 However, little is known about the clinical significance of NRP-1 expression in AML patients. Therefore, the goal of our study was to investigate the expression of NRP-1 in bone marrow of adult patients with newly diagnosed, untreated AML and to explore its possible correlation to clinical parameters.
Materials and methods

Bone marrow specimen
Seventy-six patients with newly diagnosed, untreated AML were chosen for our study. This study population is a cohort of the previously published 62 patients in whom the degree of bone marrow angiogenesis (microvessel density (MVD)) 1 and 81 patients in whom the overexpression of basic fibroblast growth factor (bFGF) have been reported. 3 All AML patients were treated within trials of the German AML Cooperative Group. 12 Thirty-eight control patients were examined as an extension from the initial group of 22 controls. 1 From all AML and control patients, a bone marrow core biopsy (iliac crest) for histological diagnosis was obtained at presentation. After every core biopsy, a bone marrow aspiration was obtained through a separate puncture for cytological analyses.
Immunohistochemical staining
For NRP-1 expression quantification, bone marrow specimens were fixed in paraformaldehyde, decalcified with ethylenediaminetetraacetic acid and embedded in paraffin. Serial sections (4 mm thick) of each sample were processed immunohistochemically for the expression of NRP-1 with rabbit polyclonal antihuman NRP-1 (Zymed No. 34-7300, San Francisco, CA, USA; working dilution 1:100). As described by the manufacturer and previously demonstrated, 13 the anti-NRP-1 antibody used in this study is specific for NRP-1. In order to demonstrate specificity, sections of renal tissues served as positive controls with specific staining of glomeruli, afferent arterioles, glomerular tufts and of proximal tubules as described before (Figure 1) . 13 Controls for immunostaining using non-immune rabbit immunoglobulin G (sc-2027; Santa Cruz Biotechnology, Santa Cruz, CA, USA) in substitution for the specific first antibodies were consistently negative (data not shown). Immunohistochemical staining was performed by the alkaline phosphatase/anti-alkaline phosphatase double bridge technique (Dako-APAAP kit, Dako, Glostrup, Denmark). Briefly, tissue sections were deparaffinized in xylene and rehydrated in a graded ethanol series. Samples were pretreated to promote antigen retrieval in a microwave oven at 450 W twice for 7 min in 10 mM sodium citrate (pH 6.0; Dako). The primary antibodies were applied overnight at 41C. Subsequent steps were performed according to the manufacturer's instructions. The fast red substrate (Dako) supplemented with 0.1% (w/v) levamisole was used for revelation of phosphatase activity (30 min at room temperature). Sections were counterstained with 0.1% (w/v) erythrocin solution.
Evaluation of NRP-1 expression
Immunostaining was simultaneously assessed by two independent experienced investigators using light microscopy. The investigators were blinded to the clinical characteristics of the patients, the results of MVD, growth factor and receptor expression when performing the receptor evaluation. Expression of NRP-1 protein was semiquantitatively assessed as described previously. 2, 3 Results are reported as arbitrary units (a.u.). In each biopsy sample, NRP-1 expression was evaluated in two to three sections processed in independent immunostainings, and the mean value was calculated. The agreement between the investigators was 98.4%. To ensure the reliability of the quantification assay, marrow slides have been randomly selected during the study and reanalyzed with excellent agreement. A bone marrow as well as renal tissue specimen served as internal control. Sections of these specimens have been repeatedly immunostained for the different antibodies and evaluated by the two investigators at different times.
Statistics
The distributions of the time-to-event variables were estimated using the Kaplan-Meier method, and comparisons were based on the log-rank test. Differences in expression of NRP-1 between AML and control group were analyzed by the Mann-Whitney rank-sum test for independent groups. Statistical significance of overall differences between more than two groups was analyzed by the Kruskal-Wallis one-way analysis of variance. Data are presented as individual data plots or as medians, interquartile ranges (low quartile-high quartile (LQ-HQ)) and ranges. Correlations between MVD, bFGF levels, VEGF levels and NRP-1 expression were assessed by the Spearman rank correlation coefficient. P-values reported are two-sided and P-values p0.05 were considered significant. All calculations were performed using the SPSS package (SPSS Inc., Chicago, IL, USA).
Results
NRP-1 expression in newly diagnosed, untreated AML patients
The expression of NRP-1 was evaluated by immunohistochemical staining in bone marrow core sections of 76 AML patients at first diagnosis. Patient characteristics are shown in Table 1 . The results from these AML patients were compared with the degree of NRP-1 protein expression in bone marrow biopsies obtained from 38 patients with different diseases but with normal bone marrow morphology. In the case of patients with underlying malignancies, the bone marrow was histologically not involved (Table 1) .
NRP-1 antigen was consistently detected in every bone marrow specimen from AML as well as control patients. Location of the immunostaining was limited to the cell membrane ( Figure 2 ). Both in AML and control specimen, megakaryocytes were stained with anti-NRP-1 antibodies as well. The NRP-1 protein staining scores of the 76 bone marrow specimens from AML patients ranged from 6 to 15 a.u. with a median value of 12.9 a.u. (LQ-HQ: 10.5-14.6), whereas control bone marrow samples (n ¼ 38) showed significantly weaker NRP-1 protein staining (median 2.75, LQ-HQ: 1.3-4.1 a.u.) (Po0.0001; Figure 3 ).
Survival data were available for 69 of 76 patients. The median overall survival for all analyzed patients was 3.6 (range 0.2-8.6) years with a 5-year overall survival rate of 24.9%. Based on the median NRP-1 expression level of the entire AML patient group, we classified patients into two groups each for patients with high (4median) and low (pmedian) NRP-1 expression. Patients with a high NRP-1 expression level (n ¼ 38) had significantly worse overall survival than those (n ¼ 31) with a low NRP-1 expression level (P ¼ 0.050). Estimated 5-year overall and relapse-free survival rates for patients with high NRP-1 expressing AML bone marrows were 16.9 and 20.9% compared to 49.6 and 46.4% for patients with low NRP-1 expression (Figure 4 ). However, Figure 1 Immunohistochemical staining of renal tissue with anti-NRP-1 antibody, which served as positive controls showing specific staining of glomeruli, afferent arterioles, glomerular tufts and of proximal tubules as described before. Neuropilin
Female patients showed significantly higher NRP-1 immunoreactivity than male patients (P ¼ 0.033). However, there was no correlation with AML subtype, karyotype, age, initial white blood cell count or the degree of leukemic blast infiltration at presentation and after induction chemotherapy. Neuropilin-1, a prognostic marker in acute myeloid leukemia M Kreuter et al marrow specimen, adjacent sections to those processed in the present study were immunostained with specific markers of endothelial cells (anti-human thrombomodulin antibodies) for the assessment of MVD and with specific antibodies for the expression of angiogenic factors; results have been reported previously. [1] [2] [3] No relation was found between NRP-1 expression and MVD (P ¼ 0.59), expression of VEGF (P ¼ 0.18), VEGFreceptor 1 (VEGFR-1) (P ¼ 0.47), VEGFR-2 (P ¼ 0.22) or bFGF (P ¼ 0.15).
Discussion
Despite progress in understanding the molecular biology of AML, its treatment remains challenging. Advances in understanding the pathophysiology of AML may lead to improvements in survival of patients with this disease. Current investigations have revealed that angiogenesis plays a significant role in the pathogenesis of AML and in the mechanisms of disease progression.
The present investigation clearly documents a significantly increased expression of NRP-1 in the bone marrow of patients with newly diagnosed, untreated AML compared with controls. Until now, NRP-1 expression has been reported in several solid tumors 6 but is not well characterized in hematological malignancies. Our data are in line with the report by Schuch et al.
11 who described NRP-1 expression on AML cell lines and in leukemic blast isolates from five patients with AML. However, this report is the first demonstrating a significant increase of NRP-1 expression in situ in the bone marrow of a large cohort of patients with newly diagnosed AML. The here described expression of the VEGF receptor NRP-1 is in line with several others reporting an increased expression of angiogenic factors in AML (reviewed by Moehler et al.
14
). MVD and VEGFR-2 expression have been reported to decline following antileukemic treatment, 1,2 whereas bFGF promotes autocrine growth stimulation of myeloid leukemic blasts. 3 Furthermore, we demonstrate a significant association of the expression of NRP-1 with survival in a large group of AML patients treated within trials by the German AML Cooperative Group. 12 Patients with a high NRP-1 expression had significant worse overall survival than patients with a low NRP-1 expression. Only some other angiogenic factors have already been identified as independent prognostic factors in AML as angiopoietin-2 expression, cellular and plasma VEGF levels and the ratio of soluble VEGF/soluble FMS-like tyrosine kinase 1 (FLt1). 5, [15] [16] [17] Although the prognostic impact of NRP-1 expression in AML was unknown so far, the prognostic value of NRP-1 expression in solid tumors has already been investigated by others. Preserved expression of NRP-1 contributes to a better prognosis in colon cancer, 18 whereas overexpression of NRP-1 correlates with poor prognosis in human glioma. 19 In non-smallcell lung cancer (NSCLC), co-expression of NRP-1 and NRP-2 is associated with poorer prognosis. 20 Nevertheless, the reason why relapse-free survival in our patients was not significantly associated with NRP-1 expression status has to be considered critically. An explanation might be that the sample size in our cohort was too small to detect significant differences. Moreover, other prognostic factors in AML as cytogenetics, subtype, overexpression of growth factors and comorbidity between both groups have to be taken into account.
However, the function of NRP-1 overexpression in AML is not well understood. In the angiogenesis pathway, NRP-1 functions as a VEGF co-receptor on endothelial cells enhancing VEGFR-2-mediated angiogenic stimuli. 21 NRP-1 expression might therefore contribute to the angiogenic phenotype in AML. In vivo overexpression of NRP-1 in rat prostate cancer resulted in enlarged tumor growth with increased MVD, dilated blood vessels, decreased numbers of apoptotic tumor cells and upregulation of VEGF expression. 22 Derived from this observation, one hypothesis to explain the mechanism of NRP-1 in AML is that NRP1 enhances storage and bioavailability of VEGF within the tumor microenvironment, thereby enhancing tumor angiogenesis in situ. Yet, the lack of correlation between NRP-1 and the expression of VEGF, VEGFR-2 and MVD in our report might argue against this assumption. However, NRP-1 expression on hematopoietic cells in fetal liver was described as a source of vascular development enhancing vasculogenesis and angiogenesis. 9 Thus, NRP-1 function might be similar in leukemia and the above named lack of correlation might be attributable to further functions of NRP-1 in AML. Furthermore, NRP-1 expression was also not associated with the expression of VEGF and other VEGFRs in human glioma and in NSCLC. 19, 20 Also a juxtracrine interaction between NRP-1-expressing blasts and neighboring bone marrow cells has to be considered. Indeed, NRP-1 was already identified as a receptor on bone marrow stromal cells and incubation of bone marrow stromal cells with VEGF led to increased expression of thrombopoietin and FLt3-ligand in these cells. 7 Recent reports have shown that VEGFdependent autocrine and paracrine loops regulate leukemia survival. 23 In accordance with the observation that NRP-1 regulates VEGF-mediated survival in breast carcinoma cells lacking other VEGFR expression, 24 NRP-1 could also act as a VEGFR on AML blasts contributing to leukemic blast survival. Additional support of this hypothesis comes from a study by Fons et al. 10 who reported that NRP-1 -together with VEGFR-2 -acts as a receptor on human bone marrow progenitor cells mediating VEGF-induced differentiation and proliferation, an effect that hypothetically might be translatable to leukemic stem cells.
Besides their function as VEGFRs, NRPs serve as co-receptors with plexins for class 3 Sema. Tordjman et al. 7 already described the expression of high levels of Sema3B, Sema3C and Sema3F on hematopoietic progenitor cells. The function of NRPs in tumorigenesis has usually been ascribed to their interactions with VEGF, but mounting evidence suggests that class 3 Sema may also be involved in angiogenesis and tumor growth, but in an inhibitory manner. 6 Sema3F, for example, was identified as a potent inhibitor of metastasis. 25 Hence, hypothetically, NRP-1 might serve as a receptor for class 3 Sema on leukemic blasts. Through a diminished secretion of inhibitory class 3 Sema, leukemic blast proliferation and/or survival could be increased. To support this hypothesis, a diminished expression of Sema3 in AML patients was already reported by Wang et al. 26 Furthermore, VEGF and Sema3A have overlapping binding domains on NRP-1 and thus are competitive inhibitors of one another. 6 A predominance of VEGF could thus lead to further enhancement of survival and proliferation of the leukemic blast population via NRP-1. A potential role of anti-NRP-1 treatment in AML has already been investigated in a murine chloroma model.
11
Treatment with soluble NRP-1, a naturally occurring protein corresponding to the NRP-1 a and b domains, inhibited tumor angiogenesis and growth; however, besides its possible role as NRP-1 antagonist, soluble NRP-1 also has to be considered as a direct VEGF-inhibitor.
In summary, we have demonstrated that AML is associated with an increased expression of NRP-1 in the bone marrow. Furthermore, a significant association between survival and NRP-1 expression was detected. Thus, our results support the Neuropilin-1, a prognostic marker in acute myeloid leukemia M Kreuter et al hypothesis of an important role for NRP-1 in AML, so that targeting NRP-1 could constitute a novel strategy in the treatment of AML. Future studies should focus on the pathomechanism of NRP-1 in AML.
